"Neutrophil activity in serum as a biomarker for multiple sclerosis" by Signe Holm Nielsen, Morten Karsdal, and Anne-Christine Bay-Jensen.
Multiple Sclerosis (MS) is a complex and debilitating autoimmune disease that affects millions worldwide. In a recent paper authored by Signe Holm Nielsen, Morten Karsdal, and Anne-Christine Bay-Jensen, a blood-based biomarker called CPa9-HNE has emerged as a promising tool for early diagnosis and personalized treatment in MS.
MS, characterized by immune-mediated inflammation within the central nervous system (CNS), has long challenged medical researchers. Existing therapies, while beneficial, have limitations in halting disease progression and preserving neurological function. The novel CPa9-HNE biomarker may provide new tools and treatment options for patients and clinicians.
In a comprehensive study, we evaluated the CPa9-HNE biomarker in two distinct MS patient groups: those with primary progressive MS (PPMS) and those with relapsing/remitting MS (RRMS), alongside healthy donors.
Highlights:
- This study is the first to quantify neutrophil activity in serum from MS patients, presenting a clinically useful diagnostic biomarker. It has the potential to fill a gap in biomarkers for clinical management and trials, aiding in the assessment of treatment eligibility for MS patients.
- The CPa9-HNE biomarker demonstrated discriminatory power. It effectively distinguished between healthy donors and patients with PPMS and RRMS, boasting an impressive Area Under the Receiver Operating Characteristic Curve (AUROC) of over 0.97. This sensitivity and specificity suggest CPa9-HNE's potential as a diagnostic tool.
- Beyond diagnosis, CPa9-HNE holds the promise of personalizing treatment strategies for MS patients. By assessing patients' neutrophil activity through this biomarker, clinicians may gain critical insights into individuals' eligibility for targeted treatments, ultimately improving therapeutic outcomes and patient quality of life.
This research conducted by Signe Holm Nielsen, Morten Karsdal, and Anne-Christine Bay-Jensen represents a another step in the fight against multiple sclerosis. Nordic Bioscience is committed to advancing the application of CPa9-HNE and similar biomarkers to empower clinicians in delivering more precise and effective treatments for MS patients.
Read the publication here
